the next biotech to run, page-6

re: what's the catch with this company Your right they do seem a good company however the revenue streams are still small and until the benefits of the many deals they have done this year start equating to strong recurring revenue streams it will languish. Although i am holding for the longer term as i think it does have a future and the directors seem to be actually procactively going to the market place within asia and creating deals.